The Filing Desk

DocGo

DCGO · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

DCGO · Last close · November 19, 2026
$0.17
Value DocGo yourself

DocGo's revenue fell 47.7% to $322 million in fiscal 2025. Its operating margin was −55.3%, down from 4.7% a year earlier. Free cash flow was $30 million, down 55.0%. It paid out $11 million in dividends and buybacks, 36% of free cash flow. The diluted share count fell 9.5%.

DocGo Inc. Latest fiscal year ended December 31, 2025 10-K filed March 16, 2026 · 0001628280-26-018214 Updated
Revenue
$322M
47.7%
Operating margin
−55.3%
59.9 pts
Net income
−$182M
$20M a year earlier
Free cash flow
$30M
55.0%
Return on capital
−84.6%
90.4 pts
Market cap
$17M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Net debt to EBITDA for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What DocGo does

DocGo provides medical care outside hospitals and clinics, and runs ambulances. Its nurses and other clinicians visit patients at home or at work for tests, vaccines, screenings and checkups, often linked by video to a physician assistant or nurse practitioner. It also offers telehealth services and remote monitoring of people with chronic conditions. Customers include health insurers, hospitals and health systems, city and state governments, and employers, in the United States and the United Kingdom.

DocGo reports two segments that earn revenue. Transportation Services, under the Ambulnz brand, moves patients between hospitals, clinics and dialysis centers, and brought in about 62% of 2025 revenue. Mobile Health Services, the home and workplace care, brought in about 38%. A growing part of that work closes "gaps in care" for insurers' Medicare and Medicaid members, such as missed screenings. DocGo competes with telehealth and in-home care firms such as Teladoc and DispatchHealth, and in ambulances with local operators, fire departments and larger firms such as Global Medical Response.

Government contracts made up about 48% of revenue in 2025, down from about three quarters the year before, as programs serving newly arrived migrants in New York wound down. At the end of 2025 DocGo had nearly 3,600 employees, most of them healthcare workers, and 582 vehicles in service in the United States and 288 in the United Kingdom.

Its biggest risks, as it describes them

  • Its heavy reliance on government contracts and a small number of large customers, which can end or shrink.
  • Large up-front costs to start work for new clients that it may not recover if relationships don't last.
  • Acquisitions that may be hard to integrate or may not bring the benefits it expects.
  • Negative press coverage that could hurt its reputation and its ability to win government contracts.
  • Value-based payment deals with insurers that tie its pay to patient outcomes and costs.
From DocGo's annual report on Form 10-K, filed March 16, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2021 to 2024, earnings per share fell 10.4% a year and net income 5.5% a year, as new shares raised the share count by 15% and diluted each share's earnings. DocGo then lost money in fiscal 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments176157598951
Debt incl. finance leases1210121517
Net debt (negative means net cash)−164−147−48−74−34
Net debt to EBITDA−9.2x−4.5x−1.5x−1.7x—
Debt to equity0.1x0.0x0.0x0.1x0.1x
Interest coverage250.4x185.5x60.2x13.4x−104.0x
Current ratio4.4x2.7x2.0x2.5x2.3x
Quick ratio4.4x2.7x2.0x2.5x2.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project DocGo's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What DocGo says to expect

  • Full year 2026: revenueFull-year 2026 revenue is expected to be approximately $300 million, compared to the Company’s prior guidance of $305-$310 million.
  • Full year 2026: adjusted EBITDAFull-year 2026 adjusted EBITDA 2 is expected to be ($17-$22) million, unchanged from last quarter.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 9, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought DocGo shares on the open market, and 1 insider sold $15,334.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Dec 15, 2025Ely D TendlerGeneral Counsel and Secretary, DirectorSold16,850$0.91$15,334Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 86 of 83 of 8
Rule of 4030.2%9.6%−38.5%
Altman Z''4.055.40−4.26
Accruals ratio16.1%−10.6%−64.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassFail
Cash from operations is positiveFailPassPass
Return on assets roseFailPassFail
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assetsPassPassFail
Current ratio roseFailPassFail
Share count didn't riseFailFailPass
Gross margin rose———
Revenue rose relative to assetsPassFailFail
F-score3 of 86 of 83 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put DocGo side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
DocGoFY25−47.7%−55.3%9.3%−84.6%—3
Fulgent GeneticsFY2513.8%−28.2%−38.5%−8.7%—4Compare
Castle BiosciencesFY253.7%−12.4%8.2%−19.1%—4Compare
CareDxFY2513.8%−8.1%—−20.0%—4Compare
Viemed HealthcareFY2520.5%8.5%4.4%12.4%−0.0x5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue94319440624617322
Revenue growth—238.7%38.2%41.7%−1.2%−47.7%
Gross profit—−133−83———
Research and development135111214
Operating income−1515221529−178
Net income−152435720−182
Diluted EPS (US$)−0.250.250.340.060.18−1.84
Diluted shares (millions)589510310610999
Cash flow
Cash from operations−11−229−647034
Capital expenditure453744
Free cash flow−15−726−726630
Dividends paid000000
Share buybacks00401411
Acquisitions013320016
Stock-based compensation—18211417
Balance sheet at fiscal year end
Cash and short-term investments32176157598951
Debt incl. finance leases81210121517
Total assets100310393490456217
Total liabilities338211418514091
Shareholders' equity55220273301321144
Margins and ratios
Gross margin—−41.7%−18.9%———
Operating margin−15.7%4.8%5.0%2.4%4.7%−55.3%
Net margin−15.7%7.5%7.8%1.1%3.2%−56.6%
Free cash flow margin−16.0%−2.1%5.8%−11.5%10.8%9.3%
Rule of 40 (growth + FCF margin)—236.6%44.0%30.2%9.6%−38.5%
Return on capital—28.2%22.3%4.8%5.8%−84.6%
Return on equity—17.3%14.0%2.4%6.4%−78.5%
Return on assets—11.6%9.8%1.6%4.2%−54.2%
Net debt to EBITDA—−9.2x−4.5x−1.5x−1.7x—
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: DocGo's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with DocGo.